Bevacizumab is more effective in nasopharyngeal carcinoma patients with lower maximum radiation dose to the temporal lobe

Nasopharyngeal carcinoma (NPC), due to its location and routes of spread, requires radiation therapy to the skull base and may include a portion of the temporal lobes of the brain in the high dose volume by virtue of its anatomic location. Radiation-induced brain necrosis (RN) usually develops months to years after radiation therapy.